Pre-Filled Syringes Market Forecast 2015-2025

LONDON, March 12, 2015 /PRNewswire/ --

Prospects for Leading Companies in Plastic Pre-Filled Syringes, Pen Injectors & Autoinjectors, and Glass Pre-Filled Syringes 

Report Details  

Pre-filled syringes - new study showing you trends, R&D progress, and predicted revenues
Where's the pre-filled syringes market heading? Visiongain's brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.

Our 250-page report provides 168 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket, injected drug and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing medical devices market.

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and STEP analysis), company profiles and commercial developments. Read the full transcripts of three exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
- Gerresheimer AG
- Richard Harrison, Business Development Manager, Injectables, Bespak Europe
- An interview with an anonymous expert from a leading pre-filled syringes manufacturer

To see a report overview please email Sara Peerun on [email protected]

Discover sales predictions for the world market and submarkets
Along with revenue and volume prediction for the overall world market, you see revenue and volume forecasts to 2025 for the following submarkets:
• Glass pre-filled syringes
• Plastic pre-filled syringes
• Pen injectors and autoinjectors.

The report also provides revenue forecasts for the following therapeutic areas of the world pharma market:
• Insulin therapies
• Rheumatoid arthritis therapies
• Multiple sclerosis therapies
• Growth hormones
• Heparins
• Vaccines
• PCSK9 inhibitors.

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for products
How will leading pre-filled injectable drugs perform to 2025 at world level? Our study forecasts sales of 11 products, including these brands:
• Lantus
• NovoRapid/NovoLog
• Humalog
• Humira
• Enbrel
• Avonex
• Rebif
• Copaxone
• Norditropin
• Genotropin
• Lovenox.

Discover how high revenues can go. You see what's happening, understanding trends, challenges and opportunities.

Our analysis also breaks the main world forecast into geographical markets.

What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 12 national markets to 2025:
• US
• Japan
• China
• Germany
• France
• UK
• Italy
• Spain
• India
• Brazil
• Russia
• Mexico
• Rest of the World

The report also provides revenue forecasts by regional market to 2025:
• US
• Japan
• EU5
• BRIC
• Rest of the World.

There will be growth in established pharma markets and in developing countries. Our analyses show that India, China, Brazil and Mexico, in particular, will continue to achieve high revenue growth to 2025. Developments worldwide in injectable drug launches and device innovation will influence the market.

To see a report overview please email Sara Peerun on [email protected]

Leading companies and potential for market growth
Overall world revenue for pre-filled syringes will reach $4.3bn in 2015, our work forecasts. We predict steady revenue growth from through to 2025. Increasing demand for chronic disease treatment, market entry of biologics and biosimilars and innovative pre-filled injection devices will increase sales to 2025.

Our work shows you what organisations hold greatest potential. See profiles of 7 leading companies, including these:
• BD
• Gerresheimer
• Schott
• SHL Group
• Ypsomed
• Datwyler
• West Pharmaceutical Services.

A company profile gives you the following information where available:
• Historical revenues for pre-filled syringe business segments from 2009 to 2014
• Discussion of a company's activities and outlook
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the pre-filled syringes industry?
Our new report discusses issues and events affecting the pre-filled syringes market. You will find discussions, including qualitative analyses:
• Increasing demand for pre-filled syringes due to increasing prevalence of chronic diseases
• A strong biologics, biosimilars and injectables pipeline
• Patent expiry and generic competition
• Regulatory aspects including human factors engineering and needlestick safety
• Pricing and reimbursement issues

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Pre-Filled Syringes Market Forecast 2015-2025: Prospects for Leading Companies in Plastic Pre-Filled Syringes, Pen Injectors & Autoinjectors, and Glass Pre-Filled Syringes report helps you
In summary, our 250-page report gives you the following knowledge:
• Revenue and volume forecasts to 2025 for the world pre-filled syringes market and 3 product categories - discover the industry's prospects, finding promising places for investments and revenues
• Revenue forecasts to 2025 for the leading 12 national markets - US, Japan, China, Germany, France, UK, Italy, Spain, India, Brazil, Russia, Mexico and Rest of the World
• Assessment of 7 leading companies - hear about products, results and strategies including revenue forecasts for pre-filled syringes business segments to 2024
• Predicted revenues for 11 leading injectable drugs to 2025 - see potentials of top products
• Predicted revenues for 7 major therapeutic areas creating demand for pre-filled syringes to 2025
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• View opinions from our survey, seeing interviews with authorities

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the pre-filled syringes market and leading companies. You find data, trends and predictions. Please order our report now.

To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1397/Pre-Filled-Syringes-Market-Forecast-2015-2025

Companies Listed In This Report 

AbbVie
Aché Laboratórios Farmacêuticos
Aesica Pharmaceuticals
AI Biosciences
Alchemia
Althea Technologies
Alverix, Inc. (acquired by BD)
Amega Biotech
Amgen
AMRI
Animas Corporation (acquired by Johnson & Johnson)
Antares Pharma
Aptar Pharma
Aptar Stelmi (part of Aptar Pharma)
Asante Solutions
Aspen Pharmacare Holdings
AstraZeneca
Baxter International
Bayer AG
Becton, Dickinson & Company (BD)
Berlin-Chemie
Bespak (subsidiary of Consort Medical)
Biocon
BioConnection
Biodel Inc.
Biogen Idec
Bioject Medical Technologies
Biopartners GmbH
Biosidus
Boehringer Ingelheim
Bristol-Myers Squibb (BMS)
Cambridge Consultants
CareFusion Corporation (acquired by BD)
Carl Zeiss Foundation
Catalent
Cato Software Solutions (acquired by BD)
Celgene Corporation
Cellnovo
Centocor (subsidiary of Johnson & Johnson)
Cipla
Consort Medical
Credence MedSystems
Crossject
D. Medical Industries
Daiichi Sankyo
Daikyo Seiko
Datwyler
Disetronic Group (acquired by Roche)
Dong-A Pharmaceutical Co. Ltd.
Dr. Reddy's Laboratories
Duoject
Eisai
Elcam Medical
Eli Lilly & Company (Lilly)
Express Scripts
Ferring Pharmaceuticals
Future Injection Technologies
Gan & Lee Pharmaceutical
GenCell Biosystems (acquired by BD)
Genentech (subsidiary of Roche)
GeneScience Pharmaceuticals
Gerresheimer
GSK
Hankook Sealtech (acquired by Datwyler)
Haselmeier
Helvoet Pharma (part of Datwyler)
Hikma Pharmaceuticals
Hospira (recently acquired by Pfizer)
Hyaluron Contract Manufacturing (acquired by AMRI)
Incyte Pharmaceuticals
Innoscan (subsidiary of the Stevanato Group)
Insulet Corporation
Jabil Circuit
Janssen Biotech (part of Johnson & Johnson)
Jefferies Group
Johnson & Johnson (J&J)
Keystone Holdings / Columbia Engineered Rubber (acquired by Datwyler)
KIESTRA Lab Automation BV (acquired by BD)
LG Life Sciences
MannKind Corporation
MedImmune (part of AstraZeneca)
Medimop Medical Projects (part of West Pharmaceutical Services)
Medtronic
Merck & Co, (Merck)
Merck Serono (Merck KGaA)
MG Sterile Products (acquired by Nipro)
MGlas (acquired by Nipro)
Mitsubishi Tanabe
Momenta Pharmaceuticals
Mylan
Natco Pharma
Nedis (part of Datwyler)
Nektar Therapeutics
Nemera (formerly Rexam)
Neutral Glass & Allied Industries (acquired by Gerresheimer)
Nipro Corporation
Nipro Medical Corporation (subsidiary of Nipro)
Novartis
Novo Nordisk
Nypro (part of Jabil Circuit)
Ompi (part of the Stevanato Group)
OPKO Health
Optrel (subsidiary of the Stevanato Group)
Oval Medical
Owen Mumford
PA Consulting Group
Palatin Technologies
Pfizer
PharmaJet
Pharmstandard
Phillips-Medsize
Plastef Investissements
Polfa-Tarchomin
Primequal
Regeneron
Revolutions Medical
Rhône Poulenc-Rorer (later subsidiary of Sanofi)
Rigel Pharmaceuticals
Roche
Roehr Products (later acquired by Brunswick Corporation)
Roselabs Bioscience (part of Roselabs Group)
Roselabs Group
ROVI
Safety Syringes (acquired by BD)
Samsung Biologics
Sandoz (division of Novartis)
Sanofi
Schering-Plough (part of Merck)
Schott AG
Schott Kaisha (Schott joint venture)
Schott Xinkang Pharmaceutical Packaging (Schott joint venture)
SciGen Ltd.
Shandong Weigao Group Medical Polymer Company (Weigao)
Shanghai Celgen Bio-Pharmaceutical
Shanghai CP Guojian
SHL Group (Scandinavian Health Ltd)
Sirigen Group Limited (acquired by BD)
SOOIL
Spami (subsidiary of the Stevanato Group)
Specialty Coating Systems
Synthon
Taisei Kako
Takeda Pharmaceutical Company
Tandem Diabetes Care
Terumo Corporation
Teva
The Medical House (acquired by Consort Medical)
The Stevanato Group
tip-top
Tonghua Dongbao
Triveni Polymers (acquired by Gerresheimer)
UCB
Unilife
Valeritas
Vedat Tampas Herméticas (now Gerresheimer Plásticos São Paulo)
Vetter Pharma
Weigao Group Pharmaceutical Packaging Products Company (subsidiary of Weigao)
West Pharmaceutical India Packaging Private (subsidiary of West Pharmaceutical Services)
West Pharmaceutical Services
Wilden Group (now Gerresheimer Regensburg)
Wockhardt
Wyeth (part of Pfizer)
Ypsomed
Zeon Corporation
Zhongding Sealtech (acquired by Datwyler)

Other Organisations Mentioned in this Report
Battelle Memorial Institute
China Food and Drug Administration (CFDA)
COFEPRIS (Mexico)
European Medicines Agency (EMA)
GAVI Alliance (formerly Global Alliance for Vaccines and Immunizations)
Johns Hopkins University
Massachusetts Institute of Technology (MIT)
Ministry of Health, Labour and Welfare (MHLW) (Japan)
Ministry of Labour and Employment (Brazil)
Pan American Health Organization (PAHO)
Parenteral Drug Association
PATH (Program for Appropriate Technology in Health)
UK National Health Service (NHS)
UNICEF (United Nations Children's Fund)
United States Food and Drug Administration (FDA)
University of Virginia
US Agency for International Development
US Centers for Disease Control and Prevention (CDC)
US Securities and Exchange Commission (SEC)
World Health Organization (WHO)

To see a report overview please email Sara Peerun on [email protected]

SOURCE Visiongain